Public synopsis
CHR-P programme — NWPT-SM32300
Informational overview of one proposed Phase 2B programme. Not medical advice. Not an offer to invest.
Last reviewed: 21 September 2026
Programme overview
NWPharmaTech’s CHR-P programme is developing NWPT-SM32300, an investigational oral cannabidiol formulation, for people experiencing symptoms associated with a clinical high risk of psychosis.
The programme is led by Professor Scott Woods of Yale University, an internationally recognised expert in early psychosis and clinical high-risk assessment.
The planned Phase 2B study is designed to evaluate dose response, symptoms, safety and tolerability, and inform the next stage of development. The proposed design includes approximately 328 participants receiving placebo or one of three daily doses over 12 weeks, with follow-up at week 16.
Our ambition is to advance earlier intervention through rigorous clinical evidence. The treatment’s effectiveness in this population has not yet been established, and study initiation remains subject to funding, finalisation and applicable approvals.
Professor Woods’s role is individual scientific/programme leadership. See Team for affiliation notes.
Effectiveness in this population has not been established. This page does not claim prevention or delay of psychosis. You cannot invest, pay, or connect a wallet on this website.
Proposed study design
Primary outcome details are being finalised. The expandable summary below lists the proposed Phase 2B design at a high level, including proposed symptom assessments, without locking which instrument is primary.
Expand: proposed Phase 2B study design
- Population: people experiencing symptoms associated with clinical high risk of psychosis (eligibility subject to final protocol and approvals).
- Arms: placebo or 300 mg, 600 mg, or 900 mg of the investigational product once daily (four arms).
- Size: approximately 328 participants.
- Duration: 12 weeks of treatment, with follow-up at week 16.
- Aims: evaluate dose response, symptoms, safety and tolerability, and inform the next stage of development.
- Proposed assessments (instruments under consideration): symptom scales such as PANSS and PSYCHS may be used among other clinical and safety assessments. Which measure is primary has not been finalised for public statement.
The investigational product is described publicly as NWPT-SM32300, an oral cannabidiol formulation (investigational 300 mg CBD micellar softgel presentation). Effectiveness has not been established.
What this is — and is not
- It is a transparent statement of one CHR-P programme organised around a planned Phase 2B study of NWPT-SM32300.
- It is not a claim that regulators have approved the design, that sites are contracted, that funding is secured, or that efficacy or prevention is established.
- Primary outcome details, sample-size assumptions and operational particulars remain under clinical finalisation; public copy will be updated when appropriate.
Financing interfaces stay inactive on this public site. See funding use for labelled planning context if needed.
Further reading
Programme · Funding use · Programme brief · Science · Evidence · Roadmap · Contact